Literature DB >> 2577144

The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors.

A J Nichols1, A C Sulpizio, D J Ashton, J P Hieble, R R Ruffolo.   

Abstract

The stereoselectivity of carvedilol, a novel beta-adrenoceptor antagonist and vasodilator with one asymmetric carbon atom, was examined at alpha 1- and beta 1-adrenoceptors in vitro and in vivo. (-)-(S)-Carvedilol is a potent, competitive antagonist of the beta 1-adrenoceptor-mediated positive chronotropic response to isoproterenol in guinea pig atrium, with a dissociation constant (KB) of 0.4 nM. (+)-(R)-Carvedilol was more than 100-fold less potent than the (-)-S-enantiomer as an antagonist of beta 1-andrenoceptors, having a KB of approximately 45 nM. Consistent with these findings (-)-(S)-carvedilol (0.1 mg/kg, i.v.) produced a 25-fold rightward shift in the beta 1-adrenoceptor-mediated positive chronotropic response to isoproterenol in pithed rats, whereas the (+)-R-enantiomer had no beta 1-adrenoceptor blocking activity in vivo at this dose. In contrast to the marked degree of stereoselectivity observed at beta 1-adrenoceptors, both (-)-(S)- and (+)-(R)-carvedilol produced equal antagonism of the alpha 1-adrenoceptor-mediated vasoconstrictor response to norepinephrine in rabbit aorta, with KB values of 14 and 16 nM, respectively. Furthermore, in the pithed rat, the alpha 1-adrenoceptor-mediated pressor dose-response curve to cirazoline was shifted approximately 6-fold to the right by both the (+)-R- and (-)-S-enantiomers of carvedilol at a dose of 1 mg/kg, i.v. In anesthetized spontaneously hypertensive rats, (-)-(S)-carvedilol was 6-fold more potent as an antihypertensive than (+)-(R)-carvedilol.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577144     DOI: 10.1002/chir.530010404

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  9 in total

1.  Partial Agonist and Biased Signaling Properties of the Synthetic Enantiomers J113863/UCB35625 at Chemokine Receptors CCR2 and CCR5.

Authors:  Jenny Corbisier; Alexandre Huszagh; Céline Galés; Marc Parmentier; Jean-Yves Springael
Journal:  J Biol Chem       Date:  2016-11-28       Impact factor: 5.157

2.  Determination and Comparison of the Solubility, Oil-Water Partition Coefficient, Intestinal Absorption, and Biliary Excretion of Carvedilol Enantiomers.

Authors:  Qi Zhang; Xin Wang; Hongjiao Xue; Baolin Huang; Zimin Lin; Zheng Cai
Journal:  AAPS PharmSciTech       Date:  2021-01-10       Impact factor: 3.246

Review 3.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 4.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 5.  Pharmacological profile of beta-adrenoceptor blockers with vasodilating properties, especially carvedilol--rationale for clinical use.

Authors:  G Sponer; W Bartsch; K Strein
Journal:  Clin Investig       Date:  1992

6.  Non-β-blocking R-carvedilol enantiomer suppresses Ca2+ waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure.

Authors:  Jingqun Zhang; Qiang Zhou; Chris D Smith; Haiyan Chen; Zhen Tan; Biyi Chen; Alma Nani; Guogen Wu; Long-Sheng Song; Michael Fill; Thomas G Back; S R Wayne Chen
Journal:  Biochem J       Date:  2015-07-08       Impact factor: 3.857

7.  Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study.

Authors:  Yo Han Kim; Hee Youn Choi; Yook-Hwan Noh; Shi Hyang Lee; Hyeong-Seok Lim; Chin Kim; Kyun-Seop Bae
Journal:  Drug Des Devel Ther       Date:  2015-06-08       Impact factor: 4.162

Review 8.  Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.

Authors:  William H Frishman; Linda S Henderson; Mary Ann Lukas
Journal:  Vasc Health Risk Manag       Date:  2008

9.  Limiting RyR2 Open Time Prevents Alzheimer's Disease-Related Neuronal Hyperactivity and Memory Loss but Not β-Amyloid Accumulation.

Authors:  Jinjing Yao; Bo Sun; Adam Institoris; Xiaoqin Zhan; Wenting Guo; Zhenpeng Song; Yajing Liu; Florian Hiess; Andrew K J Boyce; Mingke Ni; Ruiwu Wang; Henk Ter Keurs; Thomas G Back; Michael Fill; Roger J Thompson; Ray W Turner; Grant R Gordon; S R Wayne Chen
Journal:  Cell Rep       Date:  2020-09-22       Impact factor: 9.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.